Hepatitis C Assistance - MiHIN
page-template-default,page,page-id-7009,mkd-core-1.0,tribe-no-js,wellspring-ver-1.2,mkdf-smooth-scroll,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-fixed-on-scroll,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-default,mkdf-search-dropdown,wpb-js-composer js-comp-ver-4.12,vc_responsive

Hepatitis C Assistance

It is estimated that 2.7-3.9 million people in the United States have chronic Hepatitis C. Hepatitis C is fatal for one in five people. This translates to 780,000 deaths related to Hepatis C. Liver cancer and cirrhosis are common causes of death resulting from chronic Hepatitis C infection.

Direct-acting antiviral agents (DAAs) have dramatically increased cure rates for Hepatitis C virus (HCV). However, patients who have other diseases in addition to Hepatitis C (referred to as co-morbidities), or certain medical histories may not respond well to DAAs, and may require a different approach.

Clinical research has been used to create a computer model to predict the most appropriate use of DAAs based on presence of co-morbidities or specific patient histories. Predictive models can be applied to electronic health information as it moves through a Health Information Network (HIN) to identify and predict appropriate treatment for Hepatitis C in some cases.

The following document(s) are available for this scenario:

Hepatitis C Assistance Use Case Summary